The FDA approved a new three-antigen vaccine against hepatitis B virus (HBV).
The hepatitis B vaccine (recombinant) (HepB; PreHevbrio, VBI Vaccines) is indicated for the prevention of infection caused by all known subtypes of HBV in adults 18 years of age and older. PreHevbrio contains the S, pre-S2, and pre-S1 HBV surface antigens (anti-HBs), and is the only approved three-antigen HepB vaccine for U.S. adults.